Sol-Gel Technologies (SLGL)

The company is known for applying sol-gel and microencapsulation technologies to dermatology. These approaches can help control how active pharmaceutical ingredients are delivered, improve stability, and reduce irritation, which is especially relevant for conditions that require repeated or long-term topical treatment. Sol-Gel’s broader platform has supported products in areas such as acne, rosacea, and other inflammatory or genetic skin disorders.

Its pipeline includes SGT-610, also known as patidegib gel 2%, a hedgehog signaling pathway blocker being developed for chronic use in patients with Gorlin syndrome, a rare genetic condition associated with frequent basal cell carcinomas. The company is also developing SGT-210 for Darier disease and other rare keratosis-related conditions, including pachyonychia congenita, palmoplantar keratoderma, and Olmsted syndrome.

Sol-Gel operates in a pharmaceutical segment where clinical evidence, regulatory approvals, intellectual property, partnerships, and commercial execution are central to value creation. For investors, the company represents exposure to specialty dermatology, rare skin disease drug development, and the potential for differentiated topical formulations in markets with significant unmet medical need.